B. Riley Comments on biote’s Q2 Earnings (NASDAQ:BTMD)

biote Corp. (NASDAQ:BTMD) – B. Riley decreased their Q2 2025 EPS estimates for biote in a report issued on Friday, May 9th. B. Riley analyst J. Van. Sinderen now anticipates that the company will post earnings per share of $0.03 for the quarter, down from their prior forecast of $0.05. The consensus estimate for biote’s current full-year earnings is $0.75 per share. B. Riley also issued estimates for biote’s FY2027 earnings at $0.72 EPS.

biote (NASDAQ:BTMD) last released its quarterly earnings data on Wednesday, May 7th. The company reported $0.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.06 by $0.02. biote had a net margin of 5.20% and a negative return on equity of 32.41%. The company had revenue of $48.99 million during the quarter, compared to analyst estimates of $47.25 million.

Separately, Craig Hallum dropped their price objective on shares of biote from $12.00 to $8.00 and set a “buy” rating for the company in a research report on Thursday, March 13th.

biote Stock Down 2.0%

biote stock opened at $3.91 on Monday. biote has a 52-week low of $3.04 and a 52-week high of $8.44. The firm has a fifty day moving average of $3.60 and a 200-day moving average of $4.92. The firm has a market capitalization of $213.92 million, a P/E ratio of 15.04 and a beta of 1.17.

Institutional Investors Weigh In On biote

A number of large investors have recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP grew its holdings in biote by 0.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 681,524 shares of the company’s stock valued at $4,211,000 after purchasing an additional 3,065 shares in the last quarter. Jane Street Group LLC grew its holdings in biote by 24.7% during the 3rd quarter. Jane Street Group LLC now owns 16,873 shares of the company’s stock worth $94,000 after acquiring an additional 3,342 shares in the last quarter. Ameriprise Financial Inc. grew its holdings in biote by 10.2% during the 4th quarter. Ameriprise Financial Inc. now owns 36,214 shares of the company’s stock worth $224,000 after acquiring an additional 3,351 shares in the last quarter. Rhumbline Advisers grew its holdings in biote by 11.6% during the 4th quarter. Rhumbline Advisers now owns 37,688 shares of the company’s stock worth $233,000 after acquiring an additional 3,920 shares in the last quarter. Finally, Wells Fargo & Company MN grew its holdings in biote by 49.9% during the 4th quarter. Wells Fargo & Company MN now owns 12,742 shares of the company’s stock worth $79,000 after acquiring an additional 4,243 shares in the last quarter. 21.68% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at biote

In other news, major shareholder Guines Llc purchased 750,000 shares of the stock in a transaction that occurred on Thursday, March 13th. The stock was acquired at an average cost of $3.22 per share, with a total value of $2,415,000.00. Following the acquisition, the insider now owns 3,820,938 shares in the company, valued at approximately $12,303,420.36. This trade represents a 24.42% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Stephen Mark Cone purchased 38,104 shares of the stock in a transaction that occurred on Monday, March 17th. The shares were purchased at an average cost of $3.88 per share, with a total value of $147,843.52. Following the completion of the acquisition, the director now owns 160,829 shares in the company, valued at approximately $624,016.52. This represents a 31.05% increase in their position. The disclosure for this purchase can be found here. Insiders acquired 1,412,080 shares of company stock valued at $4,598,190 over the last 90 days. Corporate insiders own 24.00% of the company’s stock.

biote Company Profile

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.